File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Chronic hepatitis C virus genotype 6 infection: Response to pegylated interferon and ribavirin

TitleChronic hepatitis C virus genotype 6 infection: Response to pegylated interferon and ribavirin
Authors
Issue Date2008
PublisherOxford University Press. The Journal's web site is located at http://jid.oxfordjournals.org
Citation
Journal Of Infectious Diseases, 2008, v. 198 n. 6, p. 808-812 How to Cite?
AbstractBackground. To date, no study has evaluated pegylated interferon for the treatment of chronic infection with hepatitis C virus (HCV) genotype 6. We aimed to determine the efficacy of pegylated interferon plus ribavirin for treating infection with genotype 6 versus genotype 1. Methods. Forty-two patients chronically infected with HCV (for genotype 1, n = 21; for genotype 6, n = 21) were treated with pegylated interferon α-2a (n = 20) or α-2b (n = 22) combined with oral ribavirin for 48 weeks. Results. There was no difference between genotypes 1 and 6 in the rates of early virological response (76% vs. 81%; P > .05) and end-of-treatment response (71% vs. 81%; P > .05). Patients infected with genotype 6 had a higher rate of sustained virological response (SVR) than did patients infected with genotype 1 (86% vs. 52%; P = .019). The overall adverse-effects profile was similar in both genotype groups. There was no significant difference in the rate of SVR between patients receiving pegylated interferon α-2a and those receiving α-2b. Multivariate analysis showed that genotype was the only significant factor associated with SVR (P = .039). Conclusions. Treatment with pegylated interferon and ribavirin for 48 weeks resulted in a significantly higher rate of SVR in patients infected with genotype 6 than in those infected with genotype 1. Further studies are required to determine whether lower dosages and 24 weeks of therapy may be sufficient for the treatment of genotype 6 infection. © 2008 by the Infectious Diseases Society of America. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/59291
ISSN
2015 Impact Factor: 6.344
2015 SCImago Journal Rankings: 4.000
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorFung, Jen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorHung, Ien_HK
dc.contributor.authorYoung, Jen_HK
dc.contributor.authorCheng, Cen_HK
dc.contributor.authorWong, Den_HK
dc.contributor.authorYuen, MFen_HK
dc.date.accessioned2010-05-31T03:47:07Z-
dc.date.available2010-05-31T03:47:07Z-
dc.date.issued2008en_HK
dc.identifier.citationJournal Of Infectious Diseases, 2008, v. 198 n. 6, p. 808-812en_HK
dc.identifier.issn0022-1899en_HK
dc.identifier.urihttp://hdl.handle.net/10722/59291-
dc.description.abstractBackground. To date, no study has evaluated pegylated interferon for the treatment of chronic infection with hepatitis C virus (HCV) genotype 6. We aimed to determine the efficacy of pegylated interferon plus ribavirin for treating infection with genotype 6 versus genotype 1. Methods. Forty-two patients chronically infected with HCV (for genotype 1, n = 21; for genotype 6, n = 21) were treated with pegylated interferon α-2a (n = 20) or α-2b (n = 22) combined with oral ribavirin for 48 weeks. Results. There was no difference between genotypes 1 and 6 in the rates of early virological response (76% vs. 81%; P > .05) and end-of-treatment response (71% vs. 81%; P > .05). Patients infected with genotype 6 had a higher rate of sustained virological response (SVR) than did patients infected with genotype 1 (86% vs. 52%; P = .019). The overall adverse-effects profile was similar in both genotype groups. There was no significant difference in the rate of SVR between patients receiving pegylated interferon α-2a and those receiving α-2b. Multivariate analysis showed that genotype was the only significant factor associated with SVR (P = .039). Conclusions. Treatment with pegylated interferon and ribavirin for 48 weeks resulted in a significantly higher rate of SVR in patients infected with genotype 6 than in those infected with genotype 1. Further studies are required to determine whether lower dosages and 24 weeks of therapy may be sufficient for the treatment of genotype 6 infection. © 2008 by the Infectious Diseases Society of America. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherOxford University Press. The Journal's web site is located at http://jid.oxfordjournals.org en_HK
dc.relation.ispartofJournal of Infectious Diseasesen_HK
dc.rightsJournal of Infectious Diseases. Copyright © University of Chicago Press.en_HK
dc.subject.meshAntiviral Agents - therapeutic useen_HK
dc.subject.meshDrug Therapy, Combinationen_HK
dc.subject.meshGenotypeen_HK
dc.subject.meshHepacivirus - geneticsen_HK
dc.subject.meshHepatitis C, Chronic - drug therapy - virologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshInterferon-alpha - therapeutic useen_HK
dc.subject.meshPolyethylene Glycols - therapeutic useen_HK
dc.subject.meshRecombinant Proteinsen_HK
dc.subject.meshRibavirin - therapeutic useen_HK
dc.titleChronic hepatitis C virus genotype 6 infection: Response to pegylated interferon and ribavirinen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0022-1899&volume=198&issue=6&spage=808&epage=12&date=2008&atitle=Chronic+hepatitis+C+virus+genotype+6+infection:+response+to+pegylated+interferon+and+ribavirinen_HK
dc.identifier.emailFung, J:jfung@sicklehut.comen_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.emailHung, I:ivanhung@hkucc.hku.hken_HK
dc.identifier.emailWong, D:danywong@hku.hken_HK
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.authorityFung, J=rp00518en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.identifier.authorityHung, I=rp00508en_HK
dc.identifier.authorityWong, D=rp00492en_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1086/591252en_HK
dc.identifier.pmid18657036-
dc.identifier.scopuseid_2-s2.0-51749084677en_HK
dc.identifier.hkuros149253en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-51749084677&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume198en_HK
dc.identifier.issue6en_HK
dc.identifier.spage808en_HK
dc.identifier.epage812en_HK
dc.identifier.isiWOS:000258661500003-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridFung, J=23091109300en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridHung, I=7006103457en_HK
dc.identifier.scopusauthoridYoung, J=16949957200en_HK
dc.identifier.scopusauthoridCheng, C=24802108600en_HK
dc.identifier.scopusauthoridWong, D=7401535819en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.citeulike3083252-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats